Opinion|Videos|October 25, 2024
Proactive Steps for Mitigating GPRC5D Therapy Adverse Events
Panelists discuss how community practices establish protocols and processes for ongoing monitoring and management of potential long-term complications or adverse events from bispecific therapy.
Advertisement
Episodes in this series
- What protocols and processes do you have in place at the community practice to continue monitoring and managing potential long-term complications or adverse events associated with bispecific therapy?
Advertisement
Related to this article
Hematologic specialists discussed where ciltacabtagene autoleucel fits in the treatment paradigm at first relapse and beyond in multiple myeloma.
Updated NCCN Guidelines for multiple myeloma add a dedicated MRD testing framework and expand recommended MRD assessment timepoints.
Experts discussed whether CAR T cells or bispecific antibodies should be used first in relapsed/refractory multiple myeloma at the 2026 SOHO Annual Meeting.
Advertisement
Advertisement
Trending on CancerNetwork
1
Lutetium Lu 177 Dotatate Biosimilar Earns Final FDA Approval in GEP-NETs
2
PANXEON Liquid Biopsy Demonstrates Potential for Detecting Early Pancreatic Cancer
3
Rusfertide Earns Category 1 NCCN Recommendation in Polycythemia Vera
4
Novel Monoclonal Antibody Wins FDA Fast Track Designation in High-Risk MDS
5